OVXA Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ovoca Bio plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.029 |
| 52 Week High | €0.03 |
| 52 Week Low | €0.005 |
| Beta | 0.98 |
| 1 Month Change | 93.33% |
| 3 Month Change | 45.00% |
| 1 Year Change | 190.00% |
| 3 Year Change | -77.86% |
| 5 Year Change | -80.00% |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| OVXA | IE Pharmaceuticals | IE Market | |
|---|---|---|---|
| 7D | -1.7% | 3.5% | 2.5% |
| 1Y | 190.0% | -0.1% | 9.9% |
Return vs Industry: OVXA exceeded the Irish Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: OVXA exceeded the Irish Market which returned 8.5% over the past year.
Price Volatility
| OVXA volatility | |
|---|---|
| OVXA Average Weekly Movement | 24.5% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in IE Market | 6.3% |
| 10% least volatile stocks in IE Market | 3.2% |
Stable Share Price: OVXA's share price has been volatile over the past 3 months compared to the Irish market.
Volatility Over Time: OVXA's weekly volatility has decreased from 49% to 25% over the past year, but is still higher than 75% of Irish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 5 | Tim McCutcheon | ovocabio.com |
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It’s lead product is BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018.
Ovoca Bio plc Fundamentals Summary
| OVXA fundamental statistics | |
|---|---|
| Market cap | €2.37m |
| Earnings (TTM) | -€3.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs OVXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVXA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €3.98m |
| Earnings | -€3.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OVXA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 04:27 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ovoca Bio plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Green | Growth Equities & Company Research |